【摘要】 目的分析联用黛力新、莫沙必利和雷贝拉唑治疗慢性胃炎合并反流性食管炎的效果。方法选取我院2017年4月～2018年3月收治慢性胃炎合并反流性食管炎患者75例为研究对象。随机分为对照组37例,采用雷贝拉唑和莫沙必利治疗,观察组38例,采用黛力新、莫沙必利和雷贝拉唑治疗。比较两组患者胃、食管黏膜状态、抑郁、焦虑状态。结果治疗后观察组患者胃、食管黏膜状态显著优于对照组,差异有统计学意义(P <0.05);治疗前两组间患者SDS(忧郁自评量表)、SAS(焦虑自评量表)评分,差异无统计学意义(P> 0.05),治疗后观察组患者SDS、SAS评分显著优于对照组,差异有统计学意义(P <0.05)。结论联用黛力新、莫沙必利和雷贝拉唑治疗慢性胃炎合并反流性食管炎效果显著,可缓解患者不良情绪。更多还原

【Abstract】 Objective To analyze the effect of combined use of Deanxit,Mosapride and Rebazole in the treatment of chronic gastritis with reflux esophagitis. Methods Seventy-five patients with chronic gastritis combined with reflux esophagitis were enrolled in our hospital from April 2017 to March 2018 and divided into an observation group and a control group by random single and double counting method.37 patients of the control group were treated with Rebazole and Mosapride,and 38 patients of the observation group were treated with Deanxit,Mosapride and Rebazole.The gastric and esophageal mucosal states,depression and anxiety states were compared between the two groups. Results The gastric and esophageal mucosal states of the observation group were significantly better than those of the control group after treatment(P< 0.05).There was no significant difference in SDS(depression self-rating scale)and SAS(anxiety self-rating scale)scores between the two groups before treatment,and the difference was not statistically significant(P > 0.05).After treatment,SDS and SAS scores of the observation group were significantly better than those of the control group,and the difference was statistically significant(P < 0.05). Conclusion The combined treatment of chronic gastritis with reflux esophagitis by Deanxit,Mosapride and Rebazole is effective and helps to relieve patients’ bad mood.更多还原